Is Your Lab Ready for the FDA’s Remote Data Access Era?

The FDA’s remote regulatory assessments (RRAs) are no longer temporary pandemic measures. Over the past few years, the agency has made it clear that it expects to access pharma and biopharma data electronically as part of its evolving oversight strategy, and with publication of the Final Guidance Document, Conducting Remote Regulatory Assessments—Questions and Answers, in June 2025. For companies operating GxP labs, manufacturing facilities and QA/QC functions, this shift means one thing: digital lab systems – LIMS, ELNs, QMS, MES, CDS – are no longer just internal operational tools. They are now expected entry points for regulatory authorities.

The question is: How ready is your company to provide the FDA with secure, reliable and transparent access to your digital lab data when requested?

The End of Paper as a Safety Net

Paper-based processes and hybrid systems have long been a safety net in regulated environments. But as Axendia has argued, paper will not cut it in the FDA’s remote oversight era. Paper records introduce delays, errors and inefficiencies, and they cannot be accessed remotely.

Companies that continue to rely on manual, paper-heavy processes risk putting themselves in a defensive position during inspections. Regulators now expect to “see what your team sees” in real time, whether that means reviewing laboratory results in a LIMS, tracking deviations in a QMS or verifying manufacturing data in an MES.

Digital System Under the Spotlight

For pharma and biopharma companies, this shift raises immediate concerns:

System readiness: Are your digital lab and quality systems validated, integrated and audit-ready?

Data integrity: Can you demonstrate complete, accurate and contemporaneous data without extensive manual reconciliation?

Access protocols: Do you have secure methods to provide the FDA with remote access without exposing broader system vulnerabilities?

For technology companies supporting life science organizations with lab applications, the challenge is equally pressing: how are you equipping your clients to meet these expectations? Vendors that deliver configurable, cloud-based solutions with robust audit trails, permissioning and reporting capabilities will increasingly differentiate themselves. But technology alone is not enough. Operating companies need assurance that these systems can be implemented and maintained in ways that meet both regulatory and business needs.

Why Change is So Slow – and Why it Can’t Stay that Way

The life sciences industry’s digital transformation journey has been notoriously slow. Implementation timelines often stretch for years, with projects stalling due to budget constraints, internal resistance or the sheer complexity of change management. Meanwhile, price pressures remain high. The Inflation Reduction Act and Most Favored Nation Pricing initiative are tightening margins, forcing companies to find ways to do more with less.

Without embracing a sense of urgency, the industry risks a dangerous paradox: investing billions in R&D innovation with fragmented digital systems that don’t support regulatory review requirements. In an era when AI-driven science and digital sustainability are reshaping the lab, the bottleneck is no longer whether technology is available – it is a delay in technology adoption and implementation.

Preparing for the FDA’s Digital Expectations

So, what should pharma and biopharma companies be doing today?

Assess your digital maturity. Identify where paper and hybrid processes still dominate and prioritize digital replacements.
Strengthen your systems for inspection readiness. Ensure your LIMS, ELN, MES and QMS are validated, integrated and capable of supporting remote access
Plan for secure regulatory access. Develop clear, tested protocols for providing regulators with the data they need, without compromising IP or cybersecurity.
Invest in change management. Technology projects succeed or fail based on people. Training, communication and executive sponsorship are critical.

And for tech companies:

Build with regulatory access readiness in mind. Ensure digital tools provide transparent audit trails, role-based access and easy data sharing for inspections.
Work with your clients to develop a realistic digital strategy. Help your customers identify a clear and practical path forward, getting buy-in from all the right stakeholders from the start.
Support your customers beyond the sale. Long sales cycles and failed implementations are not just client problems – they are risks to the partnership.

The Time to Act is NOW

The FDA’s digital expectations are here today. Companies that fail to prepare will face longer inspections, higher compliance risks and delayed product launches. Those that accelerate digital adoption will be better positioned to bring therapies to market quickly and efficiently.
With patients waiting, regulators watching and price pressures mounting, the industry cannot afford to let digital transformation stall any longer.

Is your company ready for the FDA’s remote data access era? If not, the time to prepare is now, and Axendia can help you get there.

How Axendia can help:

Our team is working with bio/pharma companies and the technology vendors that serve them to bridge these gaps.
For bio/pharma companies, we support the systematic review and selection of vendors – a step that is often the biggest bottleneck. In addition, we provide guidance for a successful implementation.
We also help address the organizational side of digital transformation: change management, project management and stakeholder alignment.
For tech companies, we provide insights into what their life sciences clients truly need and how to deliver it in ways that overcome adoption hurdles. We help vendors shorten sales cycles and position their solutions for success in a regulated market.

Axendia’s Related Content:

Stay Connected with Axendia!

Stay at the forefront of innovation and technology in life sciences, healthcare, and space-enabled research by connecting with Axendia.

Follow us on LinkedIn: Join our professional network and stay updated on the latest insights, trends, and case studies. Connect with Axendia on LinkedIn
Subscribe to Our Updates: Get exclusive insights and thought leadership articles delivered straight to your inbox. Sign up for our newsletter
Share Your Thoughts: We’d love to hear from you! Contact us to discuss your ideas, challenges, or opportunities. Email Axendia

Let’s drive innovation together!

Ready to unlock new opportunities and drive success? Schedule an Analyst Inquiry

The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.